Showing results (421-430 of 550) with videos related to

Sort By:
Pageof 55
The American Journal of Tropical Medicine and Hygiene|December 5, 2012
A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicitySrilatha Edupuganti, Rachel B Eidex, Harry Keyserling, et al.
Vaccines|March 19, 2020
Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 VaccineLilin Lai, Nadine Rouphael, Yongxian Xu, et al.
Vaccine|April 16, 2024
The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sexJose L Martínez, Nicholas Lemus, Tsoi Ying Lai, et al.
Genome Biology and Evolution|February 5, 2019
Evidence of Austronesian Genetic Lineages in East Africa and South Arabia: Complex Dispersal from Madagascar and Southeast AsiaNicolas Brucato, Veronica Fernandes, Pradiptajati Kusuma, et al.
Physiological Genomics|March 15, 2012
Effect of the metabolic environment at key stages of follicle development in cattle: focus on steroid biosynthesisS W Walsh, J P Mehta, P A McGettigan, et al.
Mucosal Immunology|November 17, 2016
The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and preventionC F Kelley, C S Kraft, T Jb de Man, et al.
Vaccine|January 24, 2021
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and olderPatricia Winokur, Hana M El Sahly, Mark J Mulligan, et al.
The Journal of Infectious Diseases|February 5, 2015
Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years OldWendy A Keitel, Lisa A Jackson, Srilatha Edupuganti, et al.
Vaccines|May 7, 2025
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy AdultsAngela Branche, Mark J Mulligan, Alok Maniar, et al.
Journal of Crohn'S & Colitis|January 23, 2026
Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD servicesA Barney Hawthorne, Paul Christiansen, Ian Arnott, et al.
Pageof 55